Drugs /

avadomide

Back to Drugs List

Overview

NCI Definition [1]:
The hydrochloride salt form of CC-122, an orally available pleiotropic pathway modulator with potential antineoplastic activity.

Clinical Trials

View Clinical Trials for avadomide

Avadomide has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating avadomide, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

BCL2 Fusion, BCL6 Fusion, and EBV Positive are the most frequent biomarker inclusion criteria for avadomide clinical trials.

Diffuse large B-cell lymphoma, conjunctival melanoma, and cutaneous melanoma are the most common diseases being investigated in avadomide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Avadomide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating avadomide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pleiotropic pathway modifier cc-122 hydrochloride, cc-122 hydrochloride, cc-122 hydrochloride, cc-122
NCIT ID [1]:
C97956

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.